Cyclacel Q2 net loss $1.3M; cash $4.3M; share exchange with FITTERS on track

Bio Green Med Solution, Inc.

2025-Q2 EPS reported -$1.62

Net loss of $1.3M (incl. $7K stock comp) vs $3.3M in Q2 2024; revenue not reported.
Cash and equivalents $4.3M at June 30, 2025, estimated to fund into Q4 2025.
R&D expenses dropped to $0.1M from $2.0M after UK subsidiary liquidation in Jan 2025.
Agreed share exchange: FITTERS will exchange 100% of FITTERS Sdn. Bhd. for ~19.99% of CYCC common stock; $1M cash added; special meeting Sep 4, 2025.
In July, one-for-15 reverse stock split to meet Nasdaq bid price; $3M Series F convertible preferred raised in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.